← BackHarmony Biosciences Holdings, Inc. · DrugmakersHRMY
Low riskNext report: Due any day
The short versionA high-quality, profitable business with growing sales.
Going well
- Sales up 30% in the latest quarter vs a year ago
- Profitable, keeps 18% of sales as profit
- Sales up 22% last year
Money moves
- No insider buying or selling in the last 30 days
- Institutions cut 2.8% from their holdings in the quarter ending June 2026 (179 bought, 141 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$36.83+2.0% that day
- Company value
- $2.1B
- Share price times all shares
- Price vs profit (P/E)
- 11.9x
- You pay about $12 for each $1 of yearly profit
- Price vs sales
- 2.2x
- Company value is 2.2 times a year of sales
- Cash vs value
- 26%
- Cash as a share of company value
- Debt vs value
- 8%
- Debt as a share of company value
From HRMY's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$261.3M+30% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $959.9M, up 24% from the 12 months before. Over 5 years, sales grew about 40% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.20.8%
- PassDebt under half of equityNot relying on borrowed money.0.19x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.18.3%
- MissProfitable every yearSteady profits, not one good year.5 of 7 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$347.9M
- PassShare count not growingNot diluting owners. Falling means buybacks.-4.2% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.77.2%
- Revenue
- $868.5M
- +21.5% vs prior year
- 5-year growth
- +40.3%/yr
- revenue, per year
- Total debt
- $163.7M
- 0.19x equity
- Current ratio
- 3.60x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $261.3M
- +30.3% YoY
- EPS
- $1.28
- vs $0.68
- Op. margin
- 34.2%
- +10.2 pts
- Gross margin
- 75.8%
- -5.2 pts
- Free cash flow
- $92.4M
- Share count
- +0.6%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 1
- Normal week
- 1.0
- vs normal
- 1.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady-2.8%Institutions cut 2.8% from their holdings. 179 bought, 141 sold.
Shares held by institutions54.2M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-1.0%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.1x · $154.0M debtShares outstandingLatest reported
58MNext reportDue any dayEstimated from the same quarter last year
- Results filedAug 4
- Results filedJul 16
- Results filedMay 7
- Results filedFeb 24
- Results filedJan 12
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.